Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerNew drugs in prostate cancerDiagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic reviewClusterin: Review of research progress and looking ahead to direction in hepatocellular carcinomaChemotherapy and its evolving role in the management of advanced prostate cancerTargeting the adaptive molecular landscape of castration-resistant prostate cancerHeat shock and other apoptosis-related proteins as therapeutic targets in prostate cancerChemotherapy options in castration-resistant prostate cancerAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survivalThe Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.RNA therapeutics: beyond RNA interference and antisense oligonucleotides.Novel therapies for metastatic castrate-resistant prostate cancer.Novel drugs targeting the androgen receptor pathway in prostate cancer.The role of epithelial plasticity in prostate cancer dissemination and treatment resistanceTargeted therapy in prostate cancer.Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.Castration-resistant prostate cancer: new science and therapeutic prospects.Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials.KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer CellsClusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.Emerging targeted therapies for castration-resistant prostate cancer.Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.Future perspectives of prostate cancer therapy.The Globalization of Cooperative Groups.Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Genomic and epigenomic alterations in prostate cancer.The changing landscape in the treatment of metastatic castration-resistant prostate cancer.Novel therapies for the treatment of advanced prostate cancer.Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.Potential use of custirsen to treat prostate cancer.Twists and turns on the way to progress in metastatic castrate-resistant prostate cancerCUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Preoperative therapy for localized prostate cancer: a comprehensive overview.Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
P2860
Q21284745-84BB90A6-3ABC-44A9-99DF-1E877534E65CQ26745948-5B39F3C1-687E-46D9-A00D-FB2E06549965Q26748872-5C839C85-6B74-46F3-8340-F8D80F451BF9Q26799048-C9A512B8-4FEE-4253-947D-A70987532890Q27008883-9494C00C-2C03-4F62-928C-919C9F9E5D8DQ27022821-13D57D87-B7B5-4991-8EB4-8EE4A452E00BQ27026128-CBAC6F83-D28C-4858-ABA4-882FC966EA99Q28078477-479ED20E-9129-4DB5-BDAE-B79220436A30Q30244818-824639B9-5235-448B-AD42-DF92227F59BCQ30611108-C92F91BB-2D12-4A6B-834C-0CD2599BE625Q33438876-0FE05309-BA69-46B2-A06F-848E604D3CC4Q34248493-8FF573C1-1C1E-47EA-B1B4-8738F7CBBA19Q34249263-6CFE15F3-295E-4A90-939C-3945F9AF4750Q34395777-23D1F24E-8D68-4473-812F-5819F6D89F17Q34505037-24BF7CD4-75EC-4D8D-9E60-C880B1F6B05AQ34634763-1B47FEFF-A1C6-4D1E-939F-41D1A15220D9Q34712333-EFF35E68-C77A-4F8B-82CD-D35DD79DC51DQ35018896-E593F21F-0E71-43A0-A5FF-FF83BF52E16FQ35076264-06EF6ADD-E696-4089-95E8-1AD60CDBF2A4Q35298058-E507A86E-DECF-4F55-84E3-36B0949E4D3FQ35745925-FF76CCD1-3BE1-4F3C-B8C1-D901AC500106Q35780679-8D714C0A-A5D5-4C9B-A408-E532AC671C81Q35999255-8F12CD45-26EA-4EB3-9D4D-A029F631841CQ36019718-AD2C7810-E7B3-44ED-908B-566594AC0E06Q36072803-E3055B6D-D721-4EA8-B5F2-63C28B8DF1E6Q36076453-40C5FFA0-9581-4ABB-92F7-4E0CDF79320AQ36119749-61E2C4DA-EBAA-4C18-A2AD-2EAA665FEC4BQ36253388-809B85A0-4ADD-4B66-9C2E-A7B928CF4272Q36358303-B692FFE1-100A-4BF0-99B7-7CF244BF0751Q36374578-B507F784-3D73-4370-B9C1-E55BEA7B9EE4Q36515526-E2A5E049-6ED9-44F9-A74F-27C58F1AEA73Q36665708-AD0AC1F5-D468-4E4B-89F7-06F9543F0E38Q36848720-8A4C1E8A-DB28-4D66-AD89-10A713475EFBQ36975969-24F5338E-7525-4221-8F75-B527B2977EE4Q37084035-F0C4840B-4CC6-4D7B-9040-8DB9AFC61BCEQ37136762-D1506937-81D3-4D39-B747-7231E5A3FAB4Q37323018-23D17336-C0DE-48A0-8964-B4AA87593AC9Q37354526-7AFB2404-A7BA-438B-8865-654389E102D9Q37474516-4134B6C6-49A4-4A20-BC78-09CB159C725DQ37613445-4432CB68-4D53-4009-A1B5-9BBCEA440833
P2860
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Randomized phase II study of d ...... ion-resistant prostate cancer.
@en
Randomized phase II study of d ...... ion-resistant prostate cancer.
@nl
type
label
Randomized phase II study of d ...... ion-resistant prostate cancer.
@en
Randomized phase II study of d ...... ion-resistant prostate cancer.
@nl
prefLabel
Randomized phase II study of d ...... ion-resistant prostate cancer.
@en
Randomized phase II study of d ...... ion-resistant prostate cancer.
@nl
P2093
P356
P1476
Randomized phase II study of d ...... tion-resistant prostate cancer
@en
P2093
Dongsheng Tu
Elizabeth A Eisenhauer
Ian Tannock
Jean Powers
Martin E Gleave
Scott North
Sebastien J Hotte
P304
P356
10.1200/JCO.2009.26.8771
P407
P577
2010-08-23T00:00:00Z